Side-by-side comparison of AI visibility scores, market position, and capabilities
Non-hallucinogenic psychedelic drug developer using AI to design therapeutics without dissociation; $25.5M raised backed by OpenAI/Neuralink founders with FDA Phase I approval for MSD-001 in 2024.
Mindstate Design Labs is a Los Angeles-based clinical-stage biotech developing non-hallucinogenic psychedelic therapeutics — using computational neuroscience and machine learning to engineer psychedelic-inspired molecules that activate the neural mechanisms associated with therapeutic benefit (neuroplasticity, serotonin receptor modulation) while minimizing or eliminating the dissociative hallucinogenic effects that limit psychedelic therapy to clinical settings. A Y Combinator W21 graduate, Mindstate raised $25.5 million total, achieved $1.3 million in revenue in 2024 with a 19-person team, and received FDA and EMA approval for Phase I human trials of lead program MSD-001 in 2024, backed by founders of OpenAI, Neuralink, Coinbase, and Initialized Capital.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.